Latest Life Sciences News

Page 13 of 16
Microba Life Sciences has announced a $14.5 million capital raising, including a $2 million fully underwritten Securities Purchase Plan (SPP) and a $12.5 million Placement, aimed at fast-tracking commercialisation of its microbiome diagnostic tests in Australia and the UK.
Ada Torres
Ada Torres
27 June 2025
Microba Life Sciences Limited has had its trading suspension lifted following a capital raising announcement, signaling renewed market activity for the healthcare company.
Ada Torres
Ada Torres
23 June 2025
Microba Life Sciences announces a $12.5 million equity raise, including a strategic $8.3 million investment from Sonic Healthcare, aiming to fuel growth in the UK and achieve regional break-even by FY26.
Ada Torres
Ada Torres
23 June 2025
Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.
Ada Torres
Ada Torres
23 June 2025
Invion Limited has announced a fully underwritten entitlement offer of Loyalty Options to raise capital for advancing its cancer clinical trials. The offer, led by Blue Ocean Equities and supported by CEO Prof Thian Chew, invites eligible shareholders to participate in a non-renounceable rights issue.
Victor Sage
Victor Sage
23 June 2025
Lendlease has completed the $235 million sale of its 70% stake in Capella Capital to Sojitz Corporation, advancing its broader $2.5 billion capital recycling strategy aimed at simplifying the group and focusing on core Australian operations.
Eva Park
Eva Park
20 June 2025
EZZ Life Science has launched its US-focused brand EZZDAY with four FDA-registered supplements, marking a major step in its international growth strategy. The company has also begun US-based manufacturing and opened an online store to target American consumers.
Ada Torres
Ada Torres
19 June 2025
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.
Victor Sage
Victor Sage
18 June 2025
Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.
Victor Sage
Victor Sage
18 June 2025
Vita Life Sciences projects solid revenue growth of up to 16% for the first half of 2025, driven by strong performance in Australia, Malaysia, and Singapore, even as sales in China dip below last year’s levels.
Ada Torres
Ada Torres
17 June 2025
AnteoTech secures a significant purchase order from the Serum Institute of India, driving its Life Sciences unit toward a projected 130% sales increase in FY2025 despite some project delays.
Victor Sage
Victor Sage
12 June 2025
Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.
Victor Sage
Victor Sage
12 June 2025